Many Thanks to Give

We would like to thank our customers for choosing Allele’s products and services. The economic conditions have been challenging for the last two years and are still difficult. Allele Biotech could not have possibly achieved what it has within this time period without the support of its customers.

We thank online readers who visit our Blogs, News and Technical Forum to make our webpage one of the highest ranked among biology reagent suppliers; surpassing Clontech, Stratagene, Promega, IDT, etc. (by online ranking service Alexa’s accounts).

We thank our collaborators (some converted from customers) and business partners (manufacturers, distributors, licensors) for working with Allele and making our plan of one new product per week a reality. Allele Biotech has a very innovative and able research team, but working with researchers outside of the company is always a major part of the R&D effort at Allele.

Allele Biotech is obliged to its employees for their creativity, organization, dedication, and professionalism. The culture that they have nurtured here is to be individually motivated as a basic research group, and to be disciplined and organized as a service provider at the same time.

Allele Biotech is a beneficiary of the US government’s policies on supporting biomedical research and innovation. We appreciate the support for our basic research in the forms of grants and contracts from the NIH and the IRS, and ultimately the American tax payers. It is our duty to create and produce better tools for improving human health.

Thank you once again and have a Happy Holiday!

New Product of the Week 112210-112810:

Photoconvertible FP mClavGR (green-to-red) on lentiviral vector pLICO, email FP@allelebiotech.com for product details.

Promotion of the Wee 112210-112810:

10% additional discount off HPLC siRNA’s promotion price, $135/15 nmol, use promo code FB112210si, order by emailing oligo@allelebiotech.com.

Tags: Clontech, collaboration, collaborators, customer opinions, customer service, IDT DNA, IDT oligo, Life Technologies, mClavGR, photoconvertible FP, promega, Stratagene, thanksgiving

Competition from the Marketplace to the Courtroom

The hottest subject in the biological research equipment field has to be whole genome sequencing; hence it is no surprise that companies execute mergers and acquisitions in order to position themselves to go after their competitors in an attempt to corner this valuable market.

A bit of the background history: Illumina was started a decade ago to build DNA chip arrays by people with experience at Affymetrix, when the latter was the first and absolute leader in the DNA chip field. For years, rather than providing DNA chips, Illumina was known for generating revenue by selling oligonucleotides at 20% of the prevailing market price, essentially starting the low end oligo market. Just three or four years ago, it was a front page promotion on Invitrogen’s website to sell Illumina’s oligos through a production/shipping alliance, a cooperation previously unheard of in our field for such low price, non-commodity products. This move quite probably contributed to the decisions made by the more dedicated oligo company, IDT, to acquire local oligo production houses and move to the West coast (Allele opted out of such an acquisition and later did one of its own by taking over Orbigen and since moved into the viral systems and antibody fields). At that point when whole genome sequencing technologies were becoming mature and marketable, Illumina had performed brilliantly in out competing the previously dominant chip supplier Affymetrix, acquired Solexa, and quickly moved into the whole genome sequencing with Genome Analyzer and Genome Analyzer II, a move Affi’s management probably regretted not making.

In the years roughly around 2005-2007, Applied Biosystems, Inc. (ABI) was developing its own genome analysis equipment, the SOLiD system. It surely had a solid base to build on from its strong leadership in providing sequencer and analyzers for many years. Earlier in the year Invitrogen and ABI merged to form Life Technologies, pitching Invitrogen (now LifeTech) and Illumina in a collision course in battle for dominance in genomic analysis. In September, LifeTech brought suit against Illumina for patent infringement; in October Illumina countered with suits of its own. While the fight in court may be long and only sprinkled with occasional fireworks, the competition in the market could be fierce and should ultimately decide on whose technology is superior and offered at better prices. From the technical presentation made by sales teams to us during on site seminars, Solexa’s science sounded better. I was sitting next to Jay Flatley, CEO of Illumina at a San Diego biotech CEO dinner, and heard him predicting that the technology would advance and in a few years, one could get their own genome sequenced for about a thousand dollars, ~10% of the current cost! That’s simply innovation and competition at work. But watch out, a new wave of sequencing technologies based on single molecule capture might make the Illumina and LifeTech courtroom argument a moot point in the market.

Tags: biotech, Genome Analyzer, Illumina, Life Technologies, oligo, SOLiD, whole genome sequencing